Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.

[1]  C. Tseng.  Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes , 2017, Journal of the American Academy of Dermatology.

[2]  C. Tseng.  Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. , 2017, Diabetes & metabolism.

[3]  K. Jirström,et al.  Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study , 2016, Biology of Sex Differences.

[4]  H. Brenner,et al.  A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection , 2016, Oncotarget.

[5]  M. Saif,et al.  Metformin and pancreatic cancer: Is there a role? , 2016, Cancer Chemotherapy and Pharmacology.

[6]  R. DiPaola,et al.  Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy , 2015, Scientific Reports.

[7]  E. Raymond,et al.  Targeting cancer cell metabolism in pancreatic adenocarcinoma , 2015, Oncotarget.

[8]  D. Mukhopadhyay,et al.  Metformin Suppresses Pancreatic Tumor Growth With Inhibition of NF&kgr;B/STAT3 Inflammatory Signaling , 2015, Pancreas.

[9]  E. Holly,et al.  Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic‐based case–control study , 2015, International journal of cancer.

[10]  Zheng Wang,et al.  Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. , 2014, Diabetes research and clinical practice.